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Abstract
Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFNα2a) treatment in patients with Behcet’s
disease who were refractory to immunosuppressive agents.
Methods: This retrospective case series reviewed the medical records of 5 patients with refractory Behcet uveitis
from January 2011 to February 2017. IFNα2a was administered at a dose of 3 million IU 3 times per week. Clinical
response, relapse rate, and change of visual acuity were evaluated.
Results: The mean age of patients was 39.60 ± 9.21 years, and the median treatment duration was 6 months. Four of
the 5 patients (80%) presented with responses to IFNα2a without any uveitis attack during the treatment period. The
mean number of uveitis attacks/year per patient during the treatment was 0.40 ± 0.89. The mean log of the Minimum
Angle of Resolution visual acuity improved from 1.44 ± 0.38 at baseline to 1.02 ± 0.58 at the final follow up.
Conclusions: IFNα2a is an effective therapy for Behcet uveitis refractory to conventional immunosuppressants in
Korean patients.
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Background
Behcet’s disease (BD) is a chronic relapsing multisystem
vasculitis mainly characterized by recurrent oral ulcer-
ation, genital ulceration, ocular lesions, and skin lesions
[1]. Ocular involvement is one of the most serious com-
plication of BD, as repeated attacks of uveitis may result
in blindness [2].
Corticosteroid treatment is the mainstay in the manage-
ment of acute uveitic attacks, and immunosuppressive
agents such as cyclosporine and azathioprine are usually
effective in long-term management [3, 4]. Interferon
alpha-2a (IFNα2a) has been reported to be effective and
safe in refractory cases, although the optimal regimen has
not yet been established [5–13]. In this study, we aimed to
evaluate the efficacy of IFNα2a in Korean patients with
Behcet uveitis refractory to immunosuppressive agents.
Methods
Patients
We retrospectively reviewed the medical records of 5 pa-
tients with refractory Behcet uveitis who were treated with
IFNα2a from January 2011 to February 2017. Refractory
Behcet uveitis was defined as unresponsive or recurrent
uveitis despite combination therapy of immunosuppres-
sive agents and corticosteroids. Patients who were
followed up for at least 3 months were included in this
study. All the patients met the criteria of the International
Study Group for Behcet’s disease [14]. This study was
approved by the institutional review board of Severance
Hospital, Yonsei University College of Medicine (IRB
No.4–2017-0436).
Interferon alpha-2a treatment
IFNα2a (Roferon-A®; Roche; Basel, Switzerland) was
administered at a dose of 3 × 106 IU 3 times per week.
All previous immunomodulatory agents were stopped
the day before the initiation of IFNα2a. During IFNα2a
therapy, oral corticosteroid was tapered to a low dose
(5–10 mg/d prednisolone equivalent) or discontinued
according to a general tapering schedule (to reduce by
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5 mg/day every 1–2 weeks if the dose of prednisolone is
20-40 mg/day, to reduce by 2.5 mg/day every 1–2 weeks
if the dose is below 20 mg).
Assessments
All patients underwent a complete ophthalmologic exam-
ination, including best-corrected visual acuity (BCVA), slit
lamp biomicroscopy, tonometry, and fundoscopy. Ancil-
lary examinations included fluorescein angiography and
optical coherence tomography. Examinations were per-
formed weekly for 2 weeks, every 2 weeks for 1 month,
and then once every month. Relapse was defined as two
step increase in level of inflammation including anterior
chamber cells or vitreous haze [15]. The relapse rate was
calculated as attacks per year. Response to IFNα2a therapy
was defined as maintenance of inactive disease without
any relapse during the treatment period. The mean Log-
MAR BCVA and the mean number of uveitis attacks per
year at baseline and final visit were compared using Wil-
coxon signed-rank test. Statistical analyses were per-
formed using SPSS version 23.0 (IBM; Chicago, IL, USA)
and a p-value< 0.05 was considered statistically significant.
Results
Patients
Demographic and clinical characteristics of patients are
summarized in Table 1. The mean age of patients was
36.60 ± 9.21 years and 5 patients were male in this study.
The mean overall follow up period including the treat-
ment period was 58.80 ± 33.48 months. All patients were
Korean. Four patients (80%) presented bilateral involve-
ment. Extraocular manifestations of BD included oral
aphthous ulcers and skin lesions in all patients (100%),
genital ulcer in 1 patient (20%), gastrointestinal involve-
ment in 2 patients (40%), central nervous system
involvement in 1 patient (20%), and epididymitis in 1
patient (20%). Prior to IFNα2a therapy, 3 patients
received combination therapy of azathioprine, cyclospor-
ine, or methotrexate, and 2 patients were treated with
mycophenolate mofetil.
Interferon alpha-2a treatment
The median duration of IFNα2a treatment was 6 months
(range 2–28 months). Four (80%) of 5 patients showed
responses to IFNα2a without any uveitis attack during
the treatment period (Fig. 1). The mean number of uve-
itis attacks per year during the treatment was 0.40 ±
0.89, which decreased from 2.16 ± 1.08 before IFNα2a
therapy (p = 0.043). Four responsive patients could not
discontinue IFNα2a therapy in this study. One patient
(20%) received posterior subtenon triamcinolone injec-
tion during the treatment period. In 1 unresponsive
patient, IFNα2a was switched to infliximab. Visual acuity
improved at final visit compared with baseline in all
patients. The mean log of the Minimum Angle of Reso-
lution (logMAR) BCVA changed from 1.44 ± 0.38
Table 1 Demographic and clinical characteristics of patients with refractory Behcet uveitis
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age-range at onset (years) 20–30 40–50 20–30 30–40 30–40
Duration of IFNα2a treatment (months) 6 5 28 12 2
Overall follow-up period (months) 51 27 34 72 110
Laterality Bilateral Unilateral Bilateral Bilateral Bilateral
Anatomic classification of uveitis Panuveitis Panuveitis Panuveitis Panuveitis Panuveitis
Extraocular manifestations of BD Oral ulcer
CNS
involvement
Epididymitis
Arthritis
Skin lesion (EN)
Oral ulcer
Genital ulcer
Skin lesion(EN)
GI involvement
Oral ulcer
Skin lesion (folliculitis)
GI involvement
Oral ulcer
Skin lesion (EN)
Oral ulcer
Skin lesion(EN)
Previous immunosuppressive treatment Azathioprine
100 mg/d,
Methotrexate 17.5 mg
weekly
Cyclosporine 200 mg/d
Azathioprine 100 mg/d,
Methotrexate 17.5 mg
weekly
Cyclosporine 200
mg/d, Azathioprine
100 mg/d
Mycophenolate
mofetil 2 g/d
Mycophenolate
mofetil 2 g/d
Dose of oral corticosteroid
(mg/d prednisolone equivalent),
preTx→postTx
40→ 10 15→ 0 20→ 0 40→ 5 15→ 0
Relapse rate (number of uveitis
attacks/year), preTx→postTx
2.13→ 2 1.64→ 0 4.00→ 0 1.80→ 0 1.22→ 0
Response to IFNα2a No Yes Yes Yes Yes
Adverse events Flu-like Sx
Depression
Flu-like Sx Flu-like Sx Flu-like Sx Flu-like Sx
BD: Behcet’s disease, CNS: central nervous system, EN: erythema nodosum, GI: gastrointestinal, IFNα2a: interferon alpha-2a, Sx: symptoms, Tx: treatment
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(Snellen equivalent 20/550) at baseline to 1.02 ± 0.58
(Snellen equivalent 20/209) at final visit (p = 0.068).
Although the baseline BCVA was 20/200 or less in all
patients (100%), the final BCVA of 20/200 or less were
observed in 2 patients (40%).
Adverse events
All patients experienced flu-like symptoms at the begin-
ning of IFNα2a treatment. One patient presented with
mild depression, which was relieved by antidepressant
medication. No other significant adverse effects were
observed during the treatment period.
Discussion
In this study, we evaluated the efficacy of IFNα2a in
patients with Behcet uveitis refractory to immunosup-
pressive agents. Most patients had good responses to
IFNα2a. IFNα2a therapy was maintained in these
patients. There were no uveitis attacks during the treat-
ment period in the 4 patients who were responsive to
IFNα2a therapy. Visual acuity improved in all patients.
Corticosteroid is the main treatment option for acute
attacks of Behcet uveitis. However, its long-term use is
limited because of adverse effects. Cyclosporine and aza-
thioprine have been effectively used in Behcet uveitis
alone or combined with other immunosuppressants in
severe cases [3, 4]. There are, however, some patients
who are refractory to immunosuppressive agents, and
biological therapies including anti-tumor necrosis factor
antibody, anti-interleukin, or interferon can be consid-
ered in such cases [16, 17]. Recently, IFNα2a has been
reported to be effective for the treatment of refractory
Behcet uveitis [5, 7–13, 18, 19].
There is no consensus on the dose and protocol of
IFNα2a therapy for Behcet uveitis. In this study, we
used a lower-dose regimen of 3 × 106 IU of IFNα2a 3
times per week during the treatment period. The rate
of treatment response in our series was 80%, which is
similar to that in previous reports using higher doses of
IFNα2a [13, 19]. A lower-dose regimen may be associ-
ated with fewer treatment-related complications. There
were no severe adverse effects in the present study. In
contrast, patients with leukopenia or thrombocytopenia
have been reported in previous studies using higher
doses of IFNα2a [18, 20]. Four responsive patients
could not discontinue IFNα2a therapy in this study,
which may also have been associated with the lower
dose of the regimen. By comparison, 25–50% of pa-
tients may discontinue IFNα2a treatment with higher-
dose regimens [11, 13].
Fig. 1 Fluorescein angiographic images of patients with refractory Behcet uveitis. In patient 4, diffuse capillary leakage (a) decreased 6 months
after interferon alpha-2a (IFNα2a) therapy (b). In patient 3, moderate vascluitis at the superior arcade (c) was significantly resolved 17 months after
the initiation of IFNα2a treatment (d)
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The relapse rate of uveitis attacks significantly decreased
from 2.16 ± 1.08 to 0.40 ± 0.89 after IFNα2a therapy. In
the 4 patients who had responses to IFNα2a therapy, there
were no uveitis attacks during the treatment period. The
efficacy of IFNα2a therapy in terms of uveitis relapse was
comparable to recent reports [13, 19]. We confirmed that
treatment response without uveitis relapse may be
achieved mostly with low-dose continuous IFNα2a ther-
apy in Korean patients.
As refractory Behcet uveitis cases are rare, the major
limitations of this study are its retrospective design and
the small number of patients. We were, however, able to
confirm the efficacy of IFNα2a therapy in a uniform
low-dose regimen. Questions regarding the optimal dos-
age, treatment duration, and treatment protocol of
IFNα2a therapy still remain unanswered. A prospective
study would be necessary not only to determine the
most effective and safest protocol, but also to compare
the efficacy of IFNα2a with new biological agents cur-
rently under study.
Conclusions
IFNα2a is an effective therapeutic for Behcet uveitis re-
fractory to other immunosuppressants in Korean
patients.
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